<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Hoda Bashir on Medium]]></title>
        <description><![CDATA[Stories by Hoda Bashir on Medium]]></description>
        <link>https://medium.com/@hodabashir?source=rss-43c97c71bdd9------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Stories by Hoda Bashir on Medium</title>
            <link>https://medium.com/@hodabashir?source=rss-43c97c71bdd9------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Wed, 18 Nov 2026 07:08:29 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@hodabashir/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[I Have a Dream Deferred: Dr. Martin Luther King Jr. and Voting Rights.]]></title>
            <link>https://hodabashir.medium.com/we-celebrate-dr-kings-legacy-and-we-continue-to-fight-for-voter-s-rights-8e36dde6eff7?source=rss-43c97c71bdd9------2</link>
            <guid isPermaLink="false">https://medium.com/p/8e36dde6eff7</guid>
            <category><![CDATA[civil-rights]]></category>
            <category><![CDATA[martin-luther-king]]></category>
            <category><![CDATA[mlk]]></category>
            <category><![CDATA[voter-suppression]]></category>
            <dc:creator><![CDATA[Hoda Bashir]]></dc:creator>
            <pubDate>Mon, 17 Jan 2022 23:53:23 GMT</pubDate>
            <atom:updated>2022-01-18T00:00:17.301Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*nDeO_9JBOWlOgM9vFMTyWA.jpeg" /></figure><p>It’s the annual celebration of the Reverend Dr. Martin Luther King, Jr. The occasion will be marked with celebrations of his achievements, as it has been each year since the holiday was established in 1986. But this year feels different.</p><p>It’s not different because we are finally seeing modest progress against racially-motivated acts of violence by law enforcement communities against Black people; it’s not different because this year the holiday stands in the shadow of the anniversary of the violent and organized insurrection at the U.S. Capitol. It’s different because Dr. Martin Luther King Day, this year, occurs in the midst of a crucial battle over voting rights; a battle that progressives appear to be losing.</p><p>Dr. King lost his life to an assassin in 1968 in Memphis. That was four years after President Lyndon Johnson signed the Civil Rights Act, and three years after the President signed into law the Voting Rights Act.</p><p>For many, these laws were the culmination of Dr. King’s work, and the herald of his legacy. Dr. King knew there was a great deal of work left to do, and he was right: In the nearly six decades that have passed since the passage of the Voting Rights Act in 1965, both bills have been excoriated to different degrees. And in the wake of the Trump administration and the defeated President’s lies about election fraud, that trend has not only continued, but gained absurd, ugly momentum.</p><p>In the months after the 2020 general election, Republican lawmakers in nearly half of our states have enacted laws that will make it more difficult for marginalized people to vote. These new laws target people of color and the poor and others by limiting early voting and voting by mail; they subject voters to strict and prohibitive identification requirements; and they make it easier for election officials in those states to purge voters.</p><p>It is not a movement without resistance: voters in both the impacted states and in states that have not restricted voting have for the most part made it clear that new bills limiting the right to vote are not popular. And a federal bill to reverse disenfranchisement is stalled in the senate with near-unanimous support from the left side of the aisle and no support from the right.</p><p>It’s impossible to celebrate Martin Luther King in earnest while our lawmakers either actively restrict voting rights or fail at every effort to protect them. It makes our observation of the holiday nothing more and nothing less than a bald and shameful hypocrisy. To what degree are we being honest if we celebrate a man who has become a signifier of peace while we do nothing to protect the people whose civil liberties, their voting rights, are in such peril?</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8e36dde6eff7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What do we know about Digital Therapeutics?]]></title>
            <link>https://hodabashir.medium.com/what-do-we-know-about-digital-therapeutics-2ad6ee6acd44?source=rss-43c97c71bdd9------2</link>
            <guid isPermaLink="false">https://medium.com/p/2ad6ee6acd44</guid>
            <category><![CDATA[digital-health]]></category>
            <category><![CDATA[digital-therapeutics]]></category>
            <dc:creator><![CDATA[Hoda Bashir]]></dc:creator>
            <pubDate>Sun, 27 Jun 2021 20:11:23 GMT</pubDate>
            <atom:updated>2021-06-27T20:11:23.930Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*RvWl8KUrMzbvbtzEZLzjxA.jpeg" /></figure><p><strong>What Are Digital Therapeutics (DTx)?</strong></p><p>It’s more than telehealth, the trend that had emerged before the pandemic and took hold as the convention of care for many of us during the lockdowns and quarantines of the past year and a half. Digital therapeutics is a phrase used to reference a field of software-based tools and technology that support health. They are designed — primarily by healthcare professionals and providers — to be functional health resources that integrate seamlessly with extant or developing health and wellness plans. Digital therapeutics have been especially prevalent and beneficial among the many Americans managing chronic illnesses.</p><p>While some wellness apps and related consumer products have been considered to be “digital therapeutics,” there are some key differences. Most wellness apps have broad reach with limited definition, while most tools considered part of digital therapeutics are narrowly focused on particular aspects of health management or particular conditions. Digital therapeutics differ from wellness apps in that they can work closely with or replace other treatments, like medications and therapies. And it is only in very rare cases that an insurance company will support a carrier using a wellness app or consumer health product, while many digital therapeutics are covered by insurance plans. But the key distinction that separates digital therapeutics from consumer products is that digital therapeutics have been rigorously evaluated before they are made available, and are as scrupulously regulated as any other therapy or medication: consumer health products don’t require a prescription, while most digital therapeutics do.</p><p><strong>Not Just for the Chronically Ill</strong></p><p>While digital therapeutics have had the greatest impact on people managing chronic illnesses, and are frequently used in conjunction with behavioral health services, they have proven a very broad and versatile resource. Digital therapeutics are used to support and even administer treatment; to integrate with ongoing therapies and interventions; decrease a patient’s reliance on other potentially more invasive courses, such as pharmaceuticals and extensive therapies; provide an expanding range of healthcare and wellness options.</p><p>Some of the conditions that are being treated and managed with digital therapeutics include: asthma and related disorders; attention deficit disorder and attention deficit hyperactivity disorder; behavioral health issues; chronic pain; concussions; diabetes; hypertension; neurological disorder; obesity; sleep disorders; substance abuse, and many others.</p><p><strong>Digital Health Vs. Digital Therapeutics</strong></p><p>“Digital health” includes digital therapeutics. Digital therapeutics are one aspect of digital health. A number of other emerging conventions are also considered elements beneath the digital health umbrella. A few of them: the wearable devices that help patients manage conditions such as diabetes and heart disease; consumer wearables such as activity trackers and dietary apps; interfaces that promote personalized wellness plans; telehealth: remote appointments and monitoring; and even the technology being used to manage patient records, including prescription management.</p><p><strong>Digital Therapeutics: Safety, Evaluation, Efficacy</strong></p><p>As stated above, digital therapeutics are as strictly evaluated and regulated by health agencies as are any other medical intervention, including pharmaceuticals. Digital therapeutics conform with rigid state and federal standards, comply with regulatory agencies, and must meet precise criteria during their manufacture, distribution, and administration. An overview of the regulatory process for digital therapeutics includes, in addition to the above: Strict compliance with advertising and labeling regulations; certification by relevant regulatory agencies; and established, clinical proof that the efficacy of the therapeutic has been supported by trials and other evaluations.</p><p>As with any intervention resource, the efficacy of digital therapeutics is of the greatest importance. A treatment that is safe and regulable would have limited utility if it were not effective. Extensive testing and clinical trials must yield evidence-based affirmative proof of efficacy before a digital therapeutic is approved for use. In most cases, this means completing a randomized control trial.</p><p>A randomized control trial administers the therapeutic to participants in a clinical trial. The participants are divided: one group receives the therapeutic that is being evaluated, while another receives a placebo — this group is the “control group.” The results are then compared. For a trial of this kind to be effective, it must be randomized, the number of participants must be statistically relevant, and the trial must be conducted under the supervision — and with the authorization of — the respective agencies.</p><p><strong>How Are Digital Therapeutics Beneficial?</strong></p><p>In the simplest terms, digital therapeutics provide options and flexibility. But they do a great deal more than that. They can be a critical tool in the sustained treatment and management of a range of disorders, chronic and otherwise. Digital therapeutics also provide agency: they allow patients to be more proactive in the management of their health and wellness than they can be when relying on in-person or clinical interventions alone. Digital therapeutics also increase awareness, aid in educating patients about their health and conditions, a vital step in the process of making informed decisions about courses of treatment.</p><p>Digital therapeutics are also a crucial resource for wellness, enabling patients who are not struggling with chronic conditions with health maintenance resources, customized care, and, most essentially, the potential for early diagnosis of conditions that are or could become life-threatening.</p><p><strong>The Future of Digital Therapeutics</strong></p><p>The list of tools, resources, and interventions that are considered digital therapeutics is growing rapidly. Already, an exhaustive list would be obsolete by the time it’s completed. The COVID-19 pandemic has moved digital therapeutics from the margins to the center and they are here to stay. They have become an imperative bridge between clinical care and self-care and are bringing both well and at-risk patients into the vanguard of the most important technology and empowering them with it.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2ad6ee6acd44" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Race, Class, and Pandemics]]></title>
            <link>https://hodabashir.medium.com/race-class-and-pandemics-bbbf3574447?source=rss-43c97c71bdd9------2</link>
            <guid isPermaLink="false">https://medium.com/p/bbbf3574447</guid>
            <category><![CDATA[african-american]]></category>
            <category><![CDATA[health-inequity]]></category>
            <category><![CDATA[health-disparities]]></category>
            <category><![CDATA[structural-racism]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Hoda Bashir]]></dc:creator>
            <pubDate>Mon, 20 Apr 2020 17:34:19 GMT</pubDate>
            <atom:updated>2020-04-20T17:34:19.605Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/992/1*08bsyutT6vzeoOoqOLCUjg.jpeg" /><figcaption>Photo by Joshua Lott/Reuters</figcaption></figure><p>The long shadows of racism and inequality have darkened nearly every aspect of life in the United States, from economics to education to health and beyond. Systems that have kept African-American, Latinx, and other communities of color sequestered among the working poor have impacted those communities’ access to quality education, accurate information, stable housing, informed self-care, health insurance and care, and social supports that ameliorate the vacuum of poverty. What happens when these factors coalesce around a spiraling crisis like a global pandemic — when the lack of supports and community infrastructure exacerbate a viral outbreak that even the best-positioned communities struggle to handle?</p><p>As of the preparation of this article, COVID-19 has infected 723,605 people in the United States and caused 34,203 deaths.<a href="#_ftn1">[1]</a> Emerging data is making it clear that the virus may — as has happened many times over centuries of national trauma impacting health — break along color lines. While federal-level statistical information about the ethnic and racial distribution of COVID-19 cases and fatalities has thus far been belated, limited, and inconsistent, a clearer picture is emerging as cities such as New York City,<a href="#_ftn2">[2]</a> Chicago,<a href="#_ftn3">[3]</a> and Detroit,<a href="#_ftn4">[4]</a> among others, release detailed data.</p><p>According to CDC analysis,<a href="#_ftn5">[5]</a> African-American and Latinx Americans have a higher rate of COVID-19-related fatality than the rest of the population. In the current global epicenter of the pandemic, New York City, more Latinx people are losing their lives to the virus than any other ethnic group, per capita. Are these figures the result of centuries of economic disparity, directly and/or indirectly? The answer is more complex than that.</p><p><em>It’s More Than Just Economic Disparity</em></p><p>Economic disparities, including wages, access to support systems and reliable and affordable health insurance, as well as other direct factors continue to have an impact on health outcomes among all Americans. And economic disparity continues to have greater prevalence in African-American, Latinx, and other minority communities. But the ability of particular people and communities to adhere to social-distancing guidelines is not equal. The advised sheltering that is helping to flatten the COVID-19 curve has the greatest buy-in among middle- and upper-class communities, where white-collar, contract, and degree-dependent work is more common: for these vocations, telecommuting is more likely; for these workers, the savings, guaranteed salary, and ancillary income that make extended absence from work possible are more prevailing. For the working classes, social-distancing is frequently not an option, and that puts minority populations at risk. For those among all races and classes who must remain at work, African-Americans and other minorities of color are statistically more likely to use public transportation for their commutes,<a href="#_ftn6">[6]</a> severely restricting their ability to social-distance.</p><p>Fewer than 20% of African-American workers and roughly 15% of Latinx workers hold positions and duties that permit telecommuting, according to the Bureau of Labor Statistics. Sixty-six percent of Latinx workers report that they would struggle to be paid or even retain employment if forced to be away from duties for two or more weeks. The U.S. workforce continues to struggle toward ethnic and racial parity. The pandemic has redefined the essential workforce. More than twenty percent of all American public transit workers, grocery and market staff, food service workers, and janitors and maintenance personnel are African-American.<a href="#_ftn7">[7]</a><a href="#_ftn8">[8]</a> These workers lack the privilege of quarantine; they and their families remain exposed to the contagion daily and at high risk for infection. During crises like the one we are enduring now, fewer minorities are financially able to remove themselves from the greatest risk as have so many Americans.</p><p><em>Government and Community Messaging</em></p><p>Another factor contributing to the greater percentage of minority COVID-19 fatalities is messaging and its relative efficacy. While daily press briefings from the federal COVID-19 task force have given voice to reliable health officials, much of the Trump administration’s messaging has been dissuasive, contradictory, irrelevant, scientifically incorrect, and even hostile. Many Americans have tuned out official messaging, especially among African-Americans and Latinx people — populations historically predisposed to distrust officials that are right-leaning, white, upper-class, and apparently authoritarian. The inconsistent messaging and the suspicion with which it is received have created an information vacuum. Communities that are closer to the ground on the economic and social ladder are smaller, more insular, and more urban by the numbers: minorities live in places where much important information is self-reported. While there are benefits to this, it also means that messaging among these communities can sometimes be unreliable, transient, or incorrect. Most importantly, however, it means that social-distancing has evaporated a key source of messaging. Communities that rely on in-person exchanges have seen them silenced by the inability to congregate. Reliable information about the pandemic is not circulating among African-American, Latinx, and minority communities the way it traditionally has. And the information that is circulating is either from federal officials — dubious and given to uneven vagaries; or from social media — inconsistent and often false. Better, more reliable, and more consistent information is needed in communities that historically rely on in-person exchanges. With social-distancing guidelines slowing community outreach efforts to a trickle, the incongruous press briefings and the vicissitudes of social media remain a dangerous breeding ground for information that doesn’t benefit the communities that need reliable information most.</p><p><em>Health and Health Outcomes</em></p><p>Even if minority populations are not inherently more likely to be infected with COVID-19, they often face a more difficult recovery and poorer health outcomes than other ethnic groups. Conditions such as diabetes, heart disease, and others are more prevalent in African-American and Latinx communities<a href="#_ftn9">[9]</a> — and comorbidities like these are significant factors in the development of severe illness and death from COVID-19 infection. While genetics and environment<a href="#_ftn10">[10]</a> can be factors that contribute to health outcomes independent of social and economic conditions, these are certainly a significant influence. Access to health care, stable housing,<a href="#_ftn11">[11]</a> and reliable information about self-care and nutrition are more limited among working class populations across the board. Working class populations are also more likely to live in places where environmental conditions that impact health, such as air and water quality, are more common.</p><p>While debate rages about how prepared the U.S. should have been for the COVID-19 pandemic and whether we could have seen in coming, the ways in which the COVID-19 pandemic has impacted African-American, Latinx, and minority communities were squarely predictable. Racial and class inequalities continue to be fixed into the fabric of our society, infrastructure, and culture, and they make social crises a great deal more dangerous and more deadly for minority populations.</p><p>Conditions that have existed in this country for many years — even centuries — continue to endanger the health and health outcomes of people of color. These conditions are often practical: the necessity of exposure to health hazards and environments that neither sustain nor promote health; others are perceived: non-minority views of minority educability, self-care, and access to privileges others take for granted. Perception or praxis, the Americans that are spared the infection or the severe illness and death that can result from it are Americans with the ability to adhere to social distancing; that benefit from accurate and reliable messaging about the virus; that have and use access to health care and that are positioned to have better health outcomes because of the quality of their general health and the environment in which they live. While there is nothing inherent in being African-American, Latinx, or any minority of color that causes one to be more likely to be infected with COVID-19, economic disparity puts these populations at greater risk during this and future pandemics. And no vaccine will change that. Until the many COVID-19 deaths that have resulted from economic disparity in minority communities are taken seriously away from the context of the current pandemic, these stark health disparities will remain America’s true epidemic, the country’s real “invisible enemy,” and the threat that no one can say they didn’t see coming.</p><p><a href="#_ftnref1">[<em>1]</em></a><em> </em><a href="https://covid19.who.int/region/amro/country/us"><em>https://covid19.who.int/region/amro/country/us</em></a></p><p><a href="#_ftnref2"><em>[2]</em></a><em> </em><a href="https://www.nytimes.com/interactive/2020/04/01/nyregion/nyc-coronavirus-cases-map.html"><em>https://www.nytimes.com/interactive/2020/04/01/nyregion/nyc-coronavirus-cases-map.html</em></a></p><p><a href="#_ftnref3"><em>[3]</em></a><em> </em><a href="https://public.flourish.studio/visualisation/1812594/"><em>https://public.flourish.studio/visualisation/1812594/</em></a></p><p><a href="#_ftnref4"><em>[4]</em></a><em> </em><a href="https://www.michigan.gov/coronavirus/0,9753,7-406-98163_98173---,00.html"><em>https://www.michigan.gov/coronavirus/0,9753,7-406-98163_98173---,00.html</em></a></p><p><a href="#_ftnref5"><em>[5]</em></a><em> </em><a href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html"><em>https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html</em></a></p><p><a href="#_ftnref6"><em>[6]</em></a><em> </em><a href="https://www.pewresearch.org/fact-tank/2016/04/07/who-relies-on-public-transit-in-the-u-s/"><em>https://www.pewresearch.org/fact-tank/2016/04/07/who-relies-on-public-transit-in-the-u-s/</em></a></p><p><a href="#_ftnref7"><em>[7]</em></a><em> </em><a href="https://datausa.io/profile/soc/bus-drivers"><em>https://datausa.io/profile/soc/bus-drivers</em></a></p><p><a href="#_ftnref8"><em>[8]</em></a><em> </em><a href="https://www.mckinsey.com/featured-insights/future-of-work/the-future-of-work-in-black-america"><em>https://www.mckinsey.com/featured-insights/future-of-work/the-future-of-work-in-black-america</em></a></p><p><a href="#_ftnref9"><em>[9]</em></a><em> </em><a href="http://rashawnray.com/wp-content/uploads/2016/07/Visible-and-Invisible-Trends-in-Black-Mens-Health-Pitfalls-and-Promises-for-Addressing-Racial-Ethnic-and-Gender-Inequities-in-Health.pdf"><em>http://rashawnray.com/wp-content/uploads/2016/07/Visible-and-Invisible-Trends-in-Black-Mens-Health-Pitfalls-and-Promises-for-Addressing-Racial-Ethnic-and-Gender-Inequities-in-Health.pdf</em></a></p><p><a href="#_ftnref10"><em>[10]</em></a><em> </em><a href="http://rashawnray.com/wp-content/uploads/2018/07/Black-People-Dont-Exercise-in-my-Neighborhood_SSR_Ray.pdf"><em>http://rashawnray.com/wp-content/uploads/2018/07/Black-People-Dont-Exercise-in-my-Neighborhood_SSR_Ray.pdf</em></a></p><p><a href="#_ftnref11"><em>[11]</em></a><em> </em><a href="https://www.brookings.edu/research/devaluation-of-assets-in-black-neighborhoods/"><em>https://www.brookings.edu/research/devaluation-of-assets-in-black-neighborhoods/</em></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bbbf3574447" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What If It’s Too Late to Flatten the Curve? The Lessons of COVID-19 in the U.S.]]></title>
            <link>https://hodabashir.medium.com/what-if-its-too-late-to-flatten-the-curve-the-lessons-of-covid-19-in-the-u-s-44be17a2b791?source=rss-43c97c71bdd9------2</link>
            <guid isPermaLink="false">https://medium.com/p/44be17a2b791</guid>
            <category><![CDATA[infectious-disease]]></category>
            <category><![CDATA[public-health]]></category>
            <category><![CDATA[epidemiology]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Hoda Bashir]]></dc:creator>
            <pubDate>Tue, 31 Mar 2020 00:23:45 GMT</pubDate>
            <atom:updated>2020-03-31T01:14:32.502Z</atom:updated>
            <content:encoded><![CDATA[<p>COVID-19 has now killed more people than all 21st century worldwide epidemics (Swine Flu, MERS, Ebola, Zika, and Mumps) COMBINED. One of the reasons for the speed and potency of the virus’s overall spread may be that it has been so severe in the United States. As of the preparation of this post, there are 140,904 cases of COVID-19 in the U.S. That’s the most in the world: more than China, more than Italy. Why has it impacted the U.S. on a level disproportionate with the impact of other global pandemics? What does it mean for the severity and longevity of the outbreak in the U.S., and what are the next steps?</p><p>What is COVID-19?</p><p>“COVID-19” is a portmanteau indicating that the epidemic is the result of an infectious disease caused by a new variant on the coronavirus, and that it began in 2019. COVID-19 presents like the flu: it causes a respiratory illness including fever, coughing, and, in severe infections, difficulty breathing. It is spread primarily through direct and even indirect contact with infected people. It can spread via surfaces as well. The best practice for avoiding transmission is to wash your hands frequently, avoid touching your face, and maintain social distancing.</p><p>Is COVID-19 Like the Flu?</p><p>There are a number of important differences between COVID-19 and seasonal influenza or the flu. The flu has a very brief incubation period (no more than four days) and a rapid onset of symptoms, while COVID-19 has a relatively long incubation period (up to fourteen days) and a gradual onset of symptoms. COVID-19 carriers can be asymptomatic for a long period of time — more than two weeks counting the gradual onset of symptoms — and can spread the infection without even knowing that they have it. A carrier of the seasonal flu can be symptomatic in a day or two. People suffering from seasonal flu are contagious for up to six days, while carriers of the current coronavirus remain contagious throughout the illness — in fact they may be a great deal more contagious once symptoms appear and as they worsen. Another difference is that there’s a vaccine for the flu, and this is vital to containment. There are antiviral medications that are effective at treating seasonal flu; there are none that have been reliably tested for treatment of COVID-19.</p><p>Hospitalization and mortality rates for COVID-19 are significantly higher than for the seasonal flu, as well: around 60 of each 100,000 people who contract the flu must be hospitalized for it, and the mortality rate from the flu is less than 1%. While statistics for COVID-19 are varying widely and daily, and can be vastly different when representing different age ranges, they are reliably different from the statistics for the flu. Around 25% to 30% of COVID-19 carriers will require hospitalization: 25,000 to 30,000 of every 100,000 people; and the mortality rate for COVID-19 is around 1.77%. The staggering contrast with seasonal flu numbers insists that it’s vital that the novel coronavirus no longer be compared with influenza, in any context. It is a vastly different, more severe, and a much greater health risk than the flu. And it is concentrated, with no proven treatment and vaccine.</p><p>Why COVID-19 Spread So Quickly in the U.S.</p><p>When it comes to understanding how COVID-19 spread so quickly in the U.S., there are plenty of variables to consider. The most revealing course, however, may be to look at how the outbreak is being handled in other countries and how the response in the U.S. has diverged. Among the countries that have had relative success containing the outbreak are not necessarily those behind the U.S. in total confirmed cases — that’s now every affected country; the countries with fewer per capita infections have in most cases been successful at reducing the number of new cases daily, and have mobilized mass testing of the greatest percentage of their populations. Countries that have been successful at controlling the spread and lethality of the virus have also aggressively devoted resources and expertise to contact tracing to identify and isolate sources of local outbreaks in conjunction with hard surveillance modeling to track and control outbreaks in atomistic and more effective ways. This is simply precise tracking of the transit of the virus as it has moved from carrier to carrier. The social distancing being advised and in some cases required in the U.S. hasn’t been ineffective, but some of the countries containing the outbreak more successfully than the U.S. have done it without mass social distancing by tracing contacts and isolating local outbreaks. Mass testing, or at least testing at a greater level than the U.S. has been doing, is necessary for this.</p><p>COVID-19 in South Korea, Singapore, Taiwan, and China</p><p>Their geographical proximity to China, where the first cases of COVID-19 were reported, imperiled countries like Singapore, South Korea, and Taiwan. However, they have been successful at containing it because they responded early and rapidly, actively pursued and utilized information about the virus, and their responses were guided and focused by clear and accurate information.</p><p>South Korea has been one of the most successful countries when it comes to containing the COVID-19 outbreak. There have been more than 8,000 cases of the virus confirmed in South Korea. The first case was reported on February 20: within a week drive-through testing was active. On 03/27, South Korea reported a greater number of recovered people than new infections for the first time. They began testing early and they are testing massively, taking samples from roughly 15,000 people per day. There are nearly a hundred laboratories conducting testing nationwide. The distribution of accurate information about COVID-19 in Singapore, South Korea, and Taiwan has been open and regular: in South Korea, a widely distributed app uses GPS tracking to isolate localized outbreaks. China, Singapore, and Taiwan enforced quarantines or implemented social distancing early in the crisis with arguably greater popular adoption than in other countries, particularly western countries.</p><p>Why the U.S Has Struggled to Contain COVID-19</p><p>The U.S. responded relatively quickly with bans on travel from China and the evacuation of American officials and citizens in Wuhan. The travel ban was in time expanded to include the European Union and The United Kingdom. Minor crises with major potential impact, such as the Americans stranded aboard the Diamond Princess cruise ship, were handled with less efficacy, but handled. However, the U.S struggled and continues to struggle to test broadly enough; healthcare infrastructures appear to be unprepared for national health crises; and rapid shifts in the leadership’s response, credibility, focus, and guidance have made the country seem — and for many, feel — rudderless during an extreme national crisis.</p><p>There is a present and perhaps valid temptation to dismiss criticism of the U.S.’s response to the COVID-19 pandemic as partisan and influenced by ideology. For the purposes of understanding and appreciating the nation’s peril as the pandemic grows, what steps can be taken immediately to contain the outbreak, and what the U.S. can learn and apply relative to future global health crises, objective facts are necessary. And the objective facts condemn the current administration’s response to COVID-19. It is not a partisan perception that the U.S. has more confirmed cases of COVID-19 than any other country; it is not an ideological interpretation that the U.S. lags well behind other countries in testing; it is not an invention of the media that U.S. leadership spent weeks after the virus began to spread dismissing it as a hoax created by political opponents, underestimating its potential, and ignoring its impact: these things are not subjective.</p><p>The degree to which American leadership can be blamed for their deadly response, however, is subject to nuance and is worthy of further consideration. The U.S. has suffered prior global pandemics and health crises as remote inconveniences. Even epidemics that have had a significant impact on the U.S. have been contained among marginalized groups that the general population felt remote from (AIDS/HIV). It is valid to ask whether the current administration can be blamed for its complacency — even more valid to ask whether many of us shared it.</p><p>What’s Next?</p><p>There is a great need for hope. And there are reasons for it as well. Despite their respective perceptions of the administration’s response to the COVID-19 pandemic, Americans have been proactive in taking steps to limit the outbreak. Shelter-in-place advisories have been largely heeded by those who are able, Americans have shared both tangible and intangible resources with each other, and public health officials, governors, and other shepherds elected and unelected have emerged as leaders at a vital time. Many Americans have shown commendable resilience in adapting to necessary privation, austerity, and isolation. The country will test and confirm more, not less, and will begin to utilize the emerging data in critical ways. The less vulnerable among us who contract the virus will recover and contribute to herd immunity. There will be a vaccine.</p><p>A promising new test may be able to diagnose the novel coronavirus in as few as fifteen minutes. The test, developed by a company called Coris BioConcept isn’t perfect: it is less sensitive and less accurate than the current tests — it’s sensitivity is only 60%, meaning that it is likely to miss four out of ten positive cases of COVID-19 — but it will be a valuable tool for introducing important data into the field, allowing for quicker and deeper integration of contact tracing and modeling.</p><p>What Can We Learn?</p><p>What Happens in the U.S. During the Next Global Pandemic?</p><p>There is more reason for concern than for optimism. The pandemic is severe and is likely to get worse before it gets better. Projections are grim, life in a closed economy is difficult, and there is no reliable timetable for a return to relative normalcy. The damage to our lives and our collective health will be repaired in years, not months. We will all lose people close to us, and there is no repair for that.</p><p>But COVID-19 will be an important chapter in the history of the United States. It will be the pandemic which showed the U.S. its vulnerability, caused the nation to evaluate its perceived exceptionalism, and may be known for significant impacts in the way we are governed and how we manage our healthcare infrastructure. We may not feel the real impact of COVID-19 until there is another global pandemic — and there will inevitably be one — and we react to it with necessary urgency rather than the complacency with which we met this one.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=44be17a2b791" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Benefits of Chronic Kidney Disease Research]]></title>
            <link>https://hodabashir.medium.com/benefits-of-chronic-kidney-disease-research-24219d5d5296?source=rss-43c97c71bdd9------2</link>
            <guid isPermaLink="false">https://medium.com/p/24219d5d5296</guid>
            <category><![CDATA[kidney-disease]]></category>
            <category><![CDATA[epidemiology]]></category>
            <category><![CDATA[health-equity]]></category>
            <category><![CDATA[clinical-research]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Hoda Bashir]]></dc:creator>
            <pubDate>Mon, 21 Oct 2019 14:48:04 GMT</pubDate>
            <atom:updated>2019-10-21T14:48:14.164Z</atom:updated>
            <content:encoded><![CDATA[<p>As a kidney research professional, I’m passionate about the progress that can be made with new and ongoing research and clinical trials, as well as discouraged by the lack of data related to kidney disease, especially chronic kidney disease.</p><p>During my hands-on epidemiological field work in the United States and abroad I was able to see first hand the disproportionate representation of some minority or impoverished populations. Reaching these populations has been a guiding factor in my work and clinical research. While many studies reach and represent a broad range of people living with kidney disease, people living with chronic kidney disease, in particular, continue to be underrepresented. A high percentage of patients living with chronic kidney disease are at risk for cardiovascular morbidity and other related illnesses. It’s vitally important that this population is reached and represented in clinical trials, studies, and new therapies.</p><p>Nearly 900 million people worldwide suffer from chronic kidney disease. But many of them are excluded from clinical trials, while still more remain unaware of the extant trials and their potential benefit. Regulatory authorities often exclude chronic kidney disease sufferers from new and experimental therapies and courses. Other courses for which chronic kidney disease patients would be eligible fail to reach those who need it most, both from lack of outreach and from limited management. Including these underrepresented patients in trials and therapies benefits not only those living with chronic kidney disease, but also those who would benefit from effective and inclusive research.</p><p>Clinical trials often reach those patients for whom similar medical treatment would be prohibitively costly. These patients, once reached, benefit from positive results of trials, exposure to networks of other emerging experiments, and aid continuing research that impacts all kidney disease patients, even those not yet diagnosed. In addition, many of these trials deal not only with treatment, but with prevention. Access to chronic kidney disease sufferers is vital in using studies and clinical trials to extend all of these benefits to those patients.</p><p>Researchers are finding new ways to attract patients with chronic kidney disease to their studies: making participation more convenient by providing for transit; offering modest stipends to qualified patients; increasing outreach among underrepresented populations, including seniors and the disabled; scheduling treatments and courses more flexibly, including using remote appointments and online scheduling. But the most impactful action will take place at the person-to-person level by making new therapies and trials and their potential benefits clear, and by working to retain study participants for long-term examinations of their progress. And while not every trial will directly benefit every patient with chronic kidney disease, many of these trials will relieve some of the burden on them, either by mitigating medication costs, or by indirectly subsidizing their care and treatment.</p><p>Chronic kidney disease continues to spread, and many sufferers remain at risk of falling through the research cracks. Therapies that may be beneficial, medications that may be impactful, and treatments that could extend lives remain unproven due in part to a lack of participants. Patients fighting off chronic kidney disease — as well as researchers like me — are doing as much as they can. But collaboration can do a great deal more. The patients are out there, and the trials, research, and new therapies are out there as well. Working together to extend the benefits of chronic kidney disease studies is not only urgent, it’s a responsibility.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=24219d5d5296" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>